|Bid||1,605.00 x 175400|
|Ask||1,640.00 x 417900|
|Day's Range||1,614.50 - 1,632.00|
|52 Week Range||1,446.50 - 1,745.56|
|PE Ratio (TTM)||47.36|
|Earnings Date||Jul 26, 2017|
|Dividend & Yield||1.00 (4.66%)|
|1y Target Est||1,783.63|
Top Stock Reports for Alphabet, GlaxoSmithKline & T-Mobile
GlaxoSmithKline plc and Innoviva, Inc. today announced a submission to the European Medicines Agency for the extended use of once-daily Relvar Ellipta , an inhaled corticosteroid / long-acting β2-agonist combination, in patients already adequately controlled on an ICS/LABA combination.
GlaxoSmithKline's new chief executive, who has already made her mark with plans to divest some nutritional products, will turn next week to the main business of focusing the company's pipeline of new drugs. Despite her non-pharmaceutical background in consumer brands, Emma Walmsley sees improving drug research productivity as her top priority, and she wants Britain's biggest drugmaker to have fewer but potentially more lucrative new medicine launches in future.